4XCU
| Crystal Structure of FGFR4 with an Irreversible Inhibitor | Descriptor: | Fibroblast growth factor receptor 4, N-(2-{[6-(2,6-dichloro-3,5-dimethoxyphenyl)quinazolin-2-yl]amino}-3-methylphenyl)propanamide, SULFATE ION | Authors: | Kim, J.L, Miduturu, C, Hodous, B, Brooijmans, N, Bifulco, N, Guzi, T. | Deposit date: | 2014-12-18 | Release date: | 2015-04-01 | Last modified: | 2018-12-12 | Method: | X-RAY DIFFRACTION (1.71 Å) | Cite: | First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Cancer Discov, 5, 2015
|
|
6MUL
| Murine PI3K delta kinsae domain - cpd 1 | Descriptor: | 1-{1-[8-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-9-methyl-9H-purin-6-yl]piperidin-4-yl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one, Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Authors: | Fischmann, T.O. | Deposit date: | 2018-10-23 | Release date: | 2019-05-01 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (3.09 Å) | Cite: | Structure Overhaul Affords a Potent Purine PI3K delta Inhibitor with Improved Tolerability. J.Med.Chem., 62, 2019
|
|
6MUM
| Murine PI3K delta kinsae domain - cpd 3 | Descriptor: | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform, [(3S)-3-{[8-(1-ethyl-5-methyl-1H-pyrazol-4-yl)-9-methyl-9H-purin-6-yl]oxy}pyrrolidin-1-yl](oxan-4-yl)methanone | Authors: | Fischmann, T.O. | Deposit date: | 2018-10-23 | Release date: | 2019-05-01 | Last modified: | 2023-10-11 | Method: | X-RAY DIFFRACTION (3.06 Å) | Cite: | Structure Overhaul Affords a Potent Purine PI3K delta Inhibitor with Improved Tolerability. J.Med.Chem., 62, 2019
|
|
3PA4
| X-ray crystal structure of compound 2a bound to human CHK1 kinase domain | Descriptor: | 2-(4-chlorophenyl)-4-[(3S)-piperidin-3-ylamino]thieno[3,2-c]pyridine-7-carboxamide, GLYCEROL, Serine/threonine-protein kinase Chk1 | Authors: | Fischmann, T.O. | Deposit date: | 2010-10-18 | Release date: | 2010-12-08 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (1.59 Å) | Cite: | Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Bioorg.Med.Chem.Lett., 20, 2010
|
|
3PA5
| X-ray crystal structure of compound 1 bound to human CHK1 kinase domain | Descriptor: | 2-(carbamoylamino)-5-(4-chlorophenyl)-N-[(3S)-piperidin-3-yl]thiophene-3-carboxamide, GLYCEROL, Serine/threonine-protein kinase Chk1 | Authors: | Fischmann, T.O. | Deposit date: | 2010-10-18 | Release date: | 2010-12-08 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (1.7 Å) | Cite: | Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Bioorg.Med.Chem.Lett., 20, 2010
|
|
3PA3
| X-ray crystal structure of compound 70 bound to human CHK1 kinase domain | Descriptor: | 2-(4-chlorophenyl)-4-[(3S)-piperidin-3-ylamino]thieno[2,3-d]pyridazine-7-carboxamide, Serine/threonine-protein kinase Chk1 | Authors: | Fischmann, T.O. | Deposit date: | 2010-10-18 | Release date: | 2010-12-08 | Last modified: | 2024-02-21 | Method: | X-RAY DIFFRACTION (1.4 Å) | Cite: | Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors. Bioorg.Med.Chem.Lett., 20, 2010
|
|
9BH8
| |
9BH9
| |
9BH7
| |
9BHA
| |
9BH6
| |